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Purpose: The conversion of androgens into estrogens by aromatase is called aromatization and is inhibited by
aromatase inhibitors (AIs). The aim of this article is to evaluate the use of aromatase inhibitors in gynecological
diseases such as endometriosis, leiomyoma, estrogen- dependent gynecologic neoplasia and infertility.
Methods: This is a review of literature combined with experience and use of aromatase ınhıbıtors ın practıce
of gynecology.
Conclusion: AIs are promising agents in treatment of estrogen dependent disease. However lack of experience,
side effects and cost are limiting factors for using these agents in infertility treatment. However there is need
for larger, well designed randomized trials to generate robust data in order to establish the true potential of
aromatase inhibitors.Introduction
Estrogen is one of the primary steroid hormones for
normal female physiology and reproduction. Estrogens
(E) are mainly produced in the ovary in a reproductive-
age women. Also a small part of E is released from the
placental syncytiotrophoblasts, adipose tissue, brain, skin
fibroblasts [1].
The three important natural estrogens in women are
estrone (E1), estradiol (E2), and estriol (E3). Estradiol is
the main form of estrogen in a reproductive-age women.
Aromatase is a unique enzyme having a crucial role
during the synthesis of all estrogens from androgens [2].
The human aromatase enzyme is a member of the cyto-
chrome P450 family and expressed by the CYP19A1 gene
located on chromosome 15q21.2 [3,4]. Androstenedione
and testosterone are converted to estrogens by the enzyme
aromatase. This process called aromatization is inhibited
by aromatase inhibitors (AIs) (Figure 1).
As well as in the ovary, aromatase enzyme are avail-
able in different tissues such as adipose tissue, liver,
muscle, brain, skin, bone, endometrium, and breast tis-
sue. In late 1970s, aromatase inhibitors were used to
treat of hormone-dependent breast cancer as an alterna-
tive to adrenalectomy [5].* Correspondence: drbetuls@hotmail.com
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unless otherwise stated.First, aminoglutethimide was a first generation antiepi-
leptic in aromatase inhibitors. But cortisol replacement
was needed consequent to CYP11 inhibition by amino-
glutethimide. The use of aminoglutethimide was allowed
to side effects and the concomitant cortisol need [6].
In the treatment of breast cancer, first selective aroma-
tase inhibitor named as formestan has side effects such
as local reactions because of intramuscular administra-
tion in clinical practice [7]. This was the trigger in devel-
opment of other aromatase inhibitors.
AIs can be classified in the below table [8] (Table 1).
Nonsteroidal AIs inhibits by competing while a steroidal
AI inhibits irreversibly.
Letrozole and anastrazole restrict estrogen levels by 97
to 99% with oral administration at doses of 1 to 5 mg/day
[9]. Significant reduction of estrogen in peripheral circula-
tion by the aromatase inhibitors has been promising in the
treatment of estrogen-dependent diseases in gynecology
practice. Also the use of AIs in early follicular phase for in-
creasing the release of pituitary gonodotropin hormone
consequent to estrogen inhibition forces ovulation in in-
fertile patients.
The aim of this review is to evaluate the use of aroma-
tase inhibitors in gynecological diseases such as endo-
metriosis, leiomyoma, estrogen- dependent gynecologic
neoplasia and infertility.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Aromatase inhibitors block the aromatase cytochrome
P450 enzyme.
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Endometriosis is a common, benign, chronic and estro-
gen -dependent disease. characterized by ectopic endo-
metrial glands and stroma. Ectopic endometrial implants
is mainly located primarily on pelvic peritoneum and
ovaries [10]. Endometriosis affects 5 to 15% of asymp-
tomatic women in reproductive age. In contrast, 30 to
40% of women with infertility have been reported to
have endometriosis [11]. Aromatase inhibitors decrease
the concentration of circulating estrogens therefore FSH
secretion increases. Increased FSH is stimulatory effect on
the growth of ovarian follicles in the period of premeno-
paus [12].
Many factors such as hormonal, enviromental, genetic
and defective immune system or cancer may indicted on
the pathogenesis of endometriosis. The pathogenesis of
endometriosis is not clearly understood and many theor-
ies have been put forward. One of important theories for
pathogenesis of endometriosis suggests that; during men-
struation, there is a reflux of ectopic endometrial tissue
into the peritoneal cavity via the fallopian tubes. Studies
suggested that endometriotic lesions express aromatase
In this way provides local estrogen production in this
tissue [13].
Endometriosis demostrate a wide variety of symptoms.
The most common findings are infertility and pelvic
pain in women. Medical treatment of the disease is to
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3. Generation Letrozol Anastrozol Exemestaneand pregnancy status leading to suppression of endome-
triotic tissue. Treatment aim of endometriosis is to re-
duce pelvic pain, minimize surgical intervention, and
preserve fertility. AIs have been tried in the treatment of
symptoms. Aromatase enzime activitiy is located mainly
in the ovary and is not detectable in normal endomet-
rium and myometrium [14]. However aromatase en-
zyme activity and increased expression of the epithelial
17β-hydroxysteroid dehydrogenase type 2 enzyme (17β-
HSD2) were demonstrated in the eutopic endometrium
from women with endometriosis [15]. These two en-
zymes are two important steps in the synthesis of estra-
diol increased estrodiol directly induces prostaglandin
synthase-2 (cyclo-oxygenase-2, COX-2), which leads to
elevated concentrations of prostoglandin-E2 (PG-E2) in
endometriosis. PGE2 in turn, is the most potent known
stimulator of aromatase in endometriotic stromal cells.
Thus a positive feedback loop occur in the endometrio-
tic tissue for estrodiol synthesis. Ectopic endometrium
indicates enhanced ability of proliferation, Inflammation,
implantation and angiogenesis through increased estradiol
and PGE2 [16]. Aromatase inhibitors effectively suppress
estrogen production in the periphery (e.g., brain, adipose
tissue) and in endometriotic tissues, as well as in the ovary
and decrease circulating estrogen levels considerably.
AIs have been successfully used to treat endometriosis-
associated pelvic pain. At the studies suggested that ef-
fective dose of aromatase inhibitors for the management
of pain associated with endometriosis are usually 1 mg
daily anastrazole and 2,5 mg daily letrozole [17,18]. At
present there are same studies illustrating the efficiency
of aromatase inhibitors ın women with pain from rectova-
ginal endometriosis refractory to other medical or surgical
treatment and treating postmenopausal endometriosis
[19]. Additionally, AIs significantly reduced the size of
the endometrioma to improve pelvic pain in women
with ovarian endometriomas as measured by imaging
techniques [20].
A systematic review of eight suggested that the evi-
dence of clinical effects of aromatase inhibitors appear
to be promising in alleviating pain, reducing lesion size
and improving the quality of life in patients with endo-
metriosis. But this systematic review recommended that
more powerfull randomised controlled trials are needed
[21]. The American College of Obstetricians and Gynecol-
ogists (ACOG) committee agrees that AIs are now being
used as adjunctive therapy to GnRH analogue in women
with endometriosis resistant to conventional medical and
surgical therapies. Aromatase inhibitor regimens with
add-back progestin or oral contraceptives do not appear
to be associated with significant bone loss after 6 months
of treatment and may be suitable for long-term use. But
randomized controlled trials are needed to compare aro-
matase inhibitors with traditional medical treatment for
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of these regimens.
AIs treatment alone increases the risk of ovarian cysts
due to induction of ovarian folliculogenesis and can cause
bone loss in prolonged use. To avoid this complication in
premenopausal women, AIs need to be combined with a
progestin, a combination of oral contraceptive, or a GnRH
analogue [22]. Unfortunately recurrens of pelvic pain asso-
ciated with endometriosis is possible after aromatase in-
hibitors treatment [19].
Leiomyoma
Uterine leiomyomas are the most common benign tu-
mors of the female genital tract. The clinical incidence is
20-30% at the reproductive age of women. However the
true prevalence unknown due to more than one patholo-
gies encountered in pathology specimens. Sex steroids
and local growth factors act as the promoter and effector
of development of myomas. Aromatase enyzme is upregu-
lated in leiomyoma cells compared with normal myome-
trium [23]. Increased of aromatase leads to up-regulation
of estrogen and progesterone receptors by increasing syn-
thesis of estrogen in the myoma cells. Surgery is the main
treatment of symptomatic myoma. However, supression
of myoma symptoms by the medical treatment in peri-
menopausal period prevents stress and complications of
surgery until menopause. Aromatase inhibitors create a
local hypoestrogenic state abolishing estrogen synthesis
in leiomyoma-derived cells and inhibit the proliferation
of these cells in uterine myoma [24]. In women in the
menopausal transition, AIs reduces the size of uterine
leiomyomata and improves symptomatology [25]. The
control of the menstrual symptoms in early treatment,
even before a marked reduction in uterine volume,
shows the extent of the effect of the aromatase inhibitor
on the endometrium [26].
AIs are generally better tolerated than many hormonal
therapies without the systemic side effects observed
with GnRH analogues (phenomenon of “flare up” and
menopausal symptoms in general) [27]. Additionally, it
does not cause androgenic, progestagenic, or estrogenic
effects, such as weight gain, acne, or hypertrichosis, nor
does it alter the lipid profile [26]. The production of es-
trogen and progesterone due to gonadotropin stops and
synthesis of androgens from the adrenal gland increases
during menopause. Increased androgens are converted
to estrogen by the aromatase enzyme in adipose tissue
in obese women. Aromatase inhibitors prevent estrogen
increase by inhibiting the aromatase enzyme in obese
women. Since aromatase inhibitors are comperatively
expensive drugs, they can be preferred temporary treat-
ment in women who desire to keep their uterus or who
are not suitable for the surgical intervention [28] in
women with unexplained infertility with uterine myoma,and also in obese women who fail to respond to GnRHa
therapy [29].
Estrogen- dependent gynecologic neoplasia
Uterine sarcomas are rare forms of uterine malignancy that
originate from uterine mesenchymal elements. ER+/PR-(+)
endometrial stromal sarcoma should be treated with ad-
juvant hormonal therapy with aromatase inhibitors for
women after total abdominal hysterectomy and bilateral
salphingo – oophorectomy [30]. Endometrial hyperpla-
sia is preinvasive neoplastic lesion of endometrial can-
cer. Aromatase inhibitors are suggested to be used in
especially obese women who are diagnosed of atypical
or nonatypical endometrial hyperplasia [31]. Aromatase
activity was also demonstrated in patients with endo-
metrial cancer. Aromatase inhibitors limit this activity.
The studies demonstrated 2–10% of partial response in
recurrence endomertrial cancer with aromatase inhibi-
tors [32,33]. Etiologic role of estrogen in ovarian cancer
has also been proven [34]. In vitro data suggested that
the presence of estrogen receptor in overian tumors is
important for treating effect of aromatase inhibitors.
Aromatase inhibitors are useful in treatment of estrogen
receptor positive ovarian tumors [35].
Infertility
AI and mainly letrozole provide a new treatment option
for ovulation induction in women with anovulatory infer-
tility. They are beneficial in treating unexplained infertility
and diminished ovarian reserve. In addition, effects of AIs
are being discussed in controlled ovarian hyperstimulation
and treatment of infertility related to endometriosis.
Ovulation induction and controlled overian
hyperstimulation
Anovulatory cycles can be seen in 18–25% of women
among infertile couples [36]. The most common cause of
anovulatory cycles is polycystic ovary syndrome (PCOS)
[37]. Clomiphene citrate (CC) is currently the most com-
monly used pharmacologic agent for ovulation induction
in women, and it is approved by FDA in 1967 as the first
step of infertility treatment. CC blocks the estrogen recep-
tors centrally and eliminates the negative feedback effect
of estrogen on gonadotropins [38]. CC is easy to use and
effective in inducing ovulation in most of the patients
(60%–90%), but the pregnancy rates are disappointing
(10%–40%). This paradox has been attributed to its per-
ipheral antiestrogenic effects, mainly on the endometrium
thickness and the cervical mucus [39]. CC treatments
are also associated with risk of ovarian hyperstimulation
syndrome and multiple pregnancies (10-20%) [40]. CC
causes down regulation of estradiol receptors in the pituit-
ary, leading to oversecretion of follicle- stimulating hor-
mone. Oversecretion of this hormone causes formation of
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consequently.
CC resistance can be seen in 20-25% of anovulatory
women with PCOS as lack of response to increasing
doses of clomiphene citrat [41]. In case of clomiphene
citrate resistance, most common step is to switch ther-
apy to injectable gonadotropins. Due to disappointing
results with CC treatment, and high price and high risk
of complications of gonadotropins (like ovarian hyper-
stimulation syndrome, painful injection sites), infertility
specialists are looking for a new, easy to use, less expen-
sive, and more effective drug like aromatase inhibitors.
Letrozole is as effective as CC in ovulation induction [42].
Blocking enzyme production in the ovary by inhibiting
aromatization results in an increase in gonodotropin re-
lease in early follicular phase. AIs have much shorter half-
life (30–60 hours) compered with CC (5 days-3 weeks).
Due to rapid weakening effect of aromatase inhibitors in
the follicular phase, follicular growth is accompanied by
increased estrogen levels. Increase in estradiol allows
negative feedback onto hypothalamus and pituitary, be-
cause aromatase inhibitors do not deplete estrogen recep-
tors in the brain. Negative feedback leads to decreased
gonadotropin levels and atresia of non-dominant folli-
cules, thence increasing the chances of monofollicular
ovulation [43]. Initially, aromatase inhibitors have been
proposed as effective treatment option for anovulatory
women with clomiphene resistance and were used for in-
fertility treatment in anovulatory women in 2001. Oral ad-
ministration of letrozole, the aromatase inhibitor, was
found effective for ovulation induction in CC resistance
anovulatory infertil women and endometrial thickness was
not affected adversely [44]. Some studies have showed that
letrozole use in women resistant to clomiphene can in-
duce ovulation in more patients compared to clomiphene
[45]. In AIs treatment, cycles appeared with a better preg-
nancy rate, probably because of the lack of anti-estrogenic
effects of AIs on the endometrium [46] .
Aromatase inhibitors for subfertile women with polycys-
tic ovary syndrome were evaluated by Sebastian Frank
et al. in the Cochrane database review in terms of live
birth, OHSS, pregnancy, miscarriage and multiple preg-
nancy. Letrozole appeared to improve live birth and preg-
nancy rates in subfertile women with anovulatory PCOS,
compared to clomiphene citrate. There was not difference
in effectiveness between letrozole and laparoscopic ovar-
ian drilling. OHSS could not be evaluated because there
was not enough evidence about it [47].
Meta-analyses of six RCTs demonstrated that letrozole
improved the ovulation rate per patient; and there was
no statistical difference for the ovulation rate per cycle
or the pregnancy, live birth, multiple pregnancy or mis-
carriage rates compared with placebo or with CC plus
metformin in women with CC-resistant PCOS [48].In a study, letrozole is better than laparascopic ovarian
drilling (LOD) at six cycles for ovulation rate but differ-
ence was not found between letrozole and LOD for
pregnancy rate per patient [49]. Postoperative adhesion
formation has been documented and there are concerns
regarding the effect of LOD on long-term ovarian func-
tion [50]. Letrozole seems to be a suitable second-line
ovulation-inducing alternative to LOD in women with
PCOS who do not conceive with clomiphene citrate.
Letrozole is also an effective ovulation inducing agent in
women with higher-BMI [51]. In a study comparing oc-
currence of pregnancy among obese (body mass index:
BMI > 30) and nonobese (BMI <30) infertile women (n =
90) with different etiologies, ovulation induction with the
aromatase inhibitor letrozole (5 mg on menstrual cycle
days 3–7) followed by intrauterine insemination (IUI). As
a result, in 90 women undergoing letrozole-IUI treatment
showed greater likelihood of pregnancy in higher-BMI
group, although the difference was not significant. AIs also
are used for the treatment of unexplained infertility. Re-
cent literature supports the use of letrozole in women
who appear to be ovulatory, with similar pregnancy rates
and fewer pregnancy losses and multiple births compared
with CC [52]. In women with unexplained infertility, it ap-
pears that letrozole has similar efficacy with injectable
gonadotropins when considering ovulation, endometrial
thickness, and pregnancy rates, The randomized con-
trolled trials are showing similar pregnancy rates but with
significantly reduced costs in the letrozole group when
compared with gonadotropins [53]. In a recent study,
minimum 40 years of age infertile women (n = 159)
undergoing controlled ovarian stimulation and artificial
insemination, treated with aromatase inhibitor, letrozole
in combination with FSH, exhibited comparable preg-
nancy rates with less cancelled cycles and less FSH re-
quired for stimulation compared to FSH-treated patients
alone [54]. In addition, AIs are the promising agent to en-
hance the follicular response in women with diminished
ovarian reserve. Due to inhibition of aromatization, andro-
gens that normally converted to estrogens accumulate in
the ovary, and these androgens increase follicular sensitiv-
ity to FSH by increasing follicular FSH receptors. The
effect of remaining FSH, accelerates follicular develop-
ment [55]. Also, androgen accumulation in the follicle,
stimulates insulin-like growth factor I (IGF-I) which may
synergize with FSH to promote folliculogenesis [56]. The
improved response was clearly shown by the significantly
higher number of mature follicles and significantly lower
amount of FSH needed to achieve an adequate number of
preovulatory follicles [57]. Further treatment for breast
cancer often involves chemotherapy with alkylating
agents that can damage ovarian follicle reserve leading
to diminished ovarian reserve. For future fertility, oocyte
cryopreservation is recommended before chemotherapy.
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letrozole combined with low-dose FSH in women with
breast cancer who desired embryo cryopreservation. The
combination therapy was associated with lower peak E2
levels and a higher number of embryos [58]. Adjunctive
use of letrozole may also considered as a cost/effective
IVF protocol in these patients [59]. Garcia-Velasco et al.
was compared rFSH and highly purified hMG along with
antagonist in one group, then added 2.5 mg letrozole to
create a second group for comparison. Testosterone and
androstenedione were significantly increased in the fol-
licular fluid of the experimental group, compared with the
controls. Interestingly, E2 levels of follicular fluid were
similar with controls. These findings are consistent with
the hypothesis that aromatase inhibition, by blocking an-
drogen to convert into estrogen, increases intraovarian an-
drogens and follicular FSH receptor expression and
sensitivity to FSH administration. Also this inhibition can
be rapidly reversed. The implantation rate was higher in
the letrozole group than gonadotropins alone group (25%
and 9.4% respectively). The pregnancy rate was higher
(41.6% versus 28.9%) in letrozole group. These two results
were not statistically significant [60]. AIs are thought to be
useful in treatment of infertility associated with endomet-
riosis. In a recent pilot study, the effect of anastrazole
(coupled with goserelin) on endometriomal volume,
CA125 levels and standard IVF (in vitro fertilization)
fertility parameters were evaluated. This study demon-
strated that combined anastrazole and goserelin down-
regulation reduces endometriomal volume and serum
Ca125 which is in accordance with pregnancy and deliv-
ery but a high pregnancy loss was noted [61]. The opti-
mal dose of AIs for ovulation is unclear. The preferred
dose of letrozole (2.5) mg or anastrozole (1 mg) in many
studies were in similar with doses used for breast cancer
treatment in postmenopausal women (generally from
days 3 to 7 of menstrual cycle). The first randomized
controlled trial addressing letrozole dosing was performed
in 2007. Badawy et al. utilized either 2.5, 5, or 7.5 mg for
couples with unexplained infertility. Although they found
no differences in pregnancy or miscarriage rates, the num-
ber of mature follicles was significantly higher in the
group of women receiving 7.5 mg daily versus 5 or 2.5 mg
[62]. The mechanisms for ovulation induction are similar
for letrozole and anastrozole; both AIs are reversible,
competitive inhibitors of aromatase, with high potency
and receptor selectivity. However letrozole is the preffered
one for ovulation induction due to its higher amount of
experience about safety and teratogenicity.
Safety
AIs have been tried for ovulation induction on an off-
label basis. Food and Drug Administration (FDA) has
categorized the medication as pregnancy category D andthe label states that it is contraindicated in women of pre-
menopausal endocrine status, including pregnant women.
Initially, there were concerns about letrozole treatment
for infertility due to its teratogenic effects. Aromatase in-
hibitors are not used for ovulation induction in North
America, Europe, and other parts of the world due to lack
of knowledge about safe dose and effect on fetal toxicity,
malformations and outcome. Biljan et al. reported the out-
come of 150 babies from 130 pregnancies were compared
to a control group of over 36,000 infants born to low risk
pregnant women in a community hospital. Although there
was no difference in the overall congenital anomaly rate
between the two groups, the authors reported that the in-
cidence of cardiac and “bone” anomalies was higher in the
letrozole group than in the control group. But in this
study the control group was younger (mean age (S.D.)
30.5 ± 1.2 years) than the letrozole group (35.2 ± 4.7 years)
[63]. Conversely in another study, incidence of congenital
malformations in 911 newborn of women who conceived
after treatment with letrazole or clomiphene citrate were
compared and no statistically significant difference was
observed. Although not statistically significant, increased
risk of cardiac anomalies in newborn after ovulation in-
duction with CC was demonstrated [64]. For the half-life
of letrazole is shorter than that of CC, letrozole might be
effectively cleared from the body by the time of embryo
implantation, presumably preventing a teratogenic effect
when used in ovulation induction [65]. Complete clear-
ances are in about 10–12 days after the last dose. One
study suggests that single dose of 20 mg letrazole on cycle
day 3 had the same number of follicles generated and the
same pregnancy rate compared with multiple-dose regi-
men (doses of 5 mg given daily from cycle days 3 to 7). It
is hypothesized that administration of a high single dose
of AI in the first days of menstrual cycle would achieve
maximum estrogen suppression and also rapid clearance
of the drug would be possible before the critical final
stage of fertilization and embryogenesis[66]. In general,
AIs are well tolerated drugs with minimal side effects.
The primary adverse effects include menopausal symp-
toms (vaginal dryness, sexual dysfunction), gastrointes-
tinal events and musculoskeletal symptoms including
bone demineralization with high risk of osteoporosis
and fracture, arthralgias, and myalgias [67]. Use of aroma-
tase inhibitors are among the major risk factors of osteo-
porosis. The guidelines recommend that patients who
have a T-score > −2.0 but no additional risk factors when
AI therapy is initiated should be monitored in every 1–2
years for changes in BMD and risk status. Patients with a
T-score < −2.0 at the initiation of AI treatment should
receive bisphosphonate therapy [68]. Vitamin D and cal-
cium supplements should be given to all patients receiv-
ing AIs. AIs do not increase the risk of endometrial
cancer, thromboembolism and cerebrovascular events
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aromatase inhibitors have adverse effect on the cardio-
vascular system and lipid profiles compared with tam-
oxifen. These effects are milder or have not been seen
when comparing aromatase inhibitors with placebo but
more meticulous study is required in this area.
Conclusion
AIs are promising agents in treatment of estrogen
dependent disease. However lack of experience, side ef-
fects and cost are limiting factors for using these agents
in infertility treatment. However there is need for larger,
well designed randomized trials to generate robust data
in order to establish the true potential of aromatase
inhibitors.
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